Skymark Research Initiates Independent Research Coverage On Vion Pharmaceuticals, Inc.

CALGARY, Alberta, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Vion Pharmaceuticals, Inc.(OTCBB:VION). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com

About SMR:

Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php

About Vion Pharmaceuticals, Inc.(OTCBB:VION):

Vion Pharmaceuticals, Inc.(OTCBB:VION) is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin(tm) (laromustine) Injection and Triapine(r). The Company has submitted a New Drug Application to the FDA for Onrigin(tm) for remission induction treatment for patients sixty years of age or older with de novo poor-risk AML. The FDA's Oncologic Drug Advisory Committee has recommended to the FDA that a new randomized trial for Onrigin be completed prior to regulatory approval. Triapine(r), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

SMR Disclosure:

Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.

CONTACT:  Skymark Research
          Dylan Boyle
          202-657-6249
          info@skymarkresearch.com